**Developing novel proteomic techniques to improve early diagnostics for Coronary Heart Disease** Eliptica Limited proposes a 24 month programme of works based upon a new technique of AI-enhanced, ultrafast, low-cost mass-spectrometry (MS)-based proteomics that has been developed by its founders at the Francis Crick Institute and requires only very small amounts of blood plasma to perform high-quality, population scale, proteomic experiments. The project objective, with support from project partners Bruker UK Limited and UK Biobank, is to demonstrate that our platform can develop new insights into CVD through the application of AI to a large reference baseline of the human proteome and thus identify novel multi protein panel biomarkers (MPPB's) more quickly and accurately than is currently the case. Our MPPB's will be readily translatable into blood tests that more accurately identify patients at high risk of CVD (e.g. imminent risk of heart attack) or potentially identify the subset of patients most likely to benefit from a particular therapy. Eliptica was founded to enable Precision Medicine (i.e. to ensure the right patients receive the right treatments and medical interventions at the right time).